1227210-32-3

Basic information

• Product Name: 5-methyl-2-nitro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine
• Synonyms: 5-methyl-2-nitro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine
• CAS NO: 1227210-32-3
• Molecular Formula: C7H10N4O2
• Molecular Weight: 182.1799
• Mol File: 1227210-32-3.mol
• Article Data: 13

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-methyl-2-nitro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-methyl-2-nitro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine(1227210-32-3)
• EPA Substance Registry System: 5-methyl-2-nitro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine(1227210-32-3)

Safety Data

• Hazardous Substances Data: 1227210-32-3(Hazardous Substances Data)

Upstream product

• 1360057-00-6 methyl 1-(2-bromoethyl)-3-nitro-1H-pyrazole-5-carboxylate 
• 1408327-48-9 5-methyl-2-nitro-6,7-dihydropyrazolo[1,5-a]pyrazine-4(5H)-one 
• 1227210-30-1 (1-(2-bromoethyl)-3-nitro-1H-pyrazole-5-yl)methanol 
• 1227210-31-2 1-(2-bromoethyl)-5-(bromomethyl)-3-nitro-1H-pyrazole 
• 74-89-5 methylamine 

Downstream Products

• 1227210-33-4 5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl-amine 

Relevant articles and documents

A concise synthesis of a tetrahydropyrazolopyrazine building block

A concise synthesis of a tetrahydropyrazolopyrazine building block is described. 5-Methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamine was prepared in three steps and 80% yield from 5-nitro-2H-pyrazole-3-carboxylic acid. This compound was then coupled with 4-bromo-6-chloro-2-methyl-2H- pyridazin-3-one in the presence of sodium tert-pentoxide to give the target product in 87% yield. The process was successfully scaled up to a multihundred gram scale.

Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability

BTK inhibitor GDC-0834 (1) was found to be rapidly metabolized in human studies, resulting in a suspension of clinical trials. The primary route of metabolism was through cleavage of the acyclic amide bond connecting the terminal tetrahydrobenzothiophene

HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY

Heteroaryl pyridone and aza-pyridone compounds of Formula I are provided, where one or two of X, X, and Xare N, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I foranddiagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.